AR070375A1 - Sistemas de administracion de drogas que contienen estradiol - Google Patents

Sistemas de administracion de drogas que contienen estradiol

Info

Publication number
AR070375A1
AR070375A1 ARP090100515A ARP090100515A AR070375A1 AR 070375 A1 AR070375 A1 AR 070375A1 AR P090100515 A ARP090100515 A AR P090100515A AR P090100515 A ARP090100515 A AR P090100515A AR 070375 A1 AR070375 A1 AR 070375A1
Authority
AR
Argentina
Prior art keywords
estradiol
drug administration
systems containing
film matrix
administration systems
Prior art date
Application number
ARP090100515A
Other languages
English (en)
Inventor
Adrian Funke
Sascha General
Christian Zurth
Idiko Terebesi
Sofia Alincic-Kunz
Thomas Holler
Matthias Schaefer
Konstanze Diefenbach
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR070375A1 publication Critical patent/AR070375A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Reivindicacion 1: Una forma de dosificacion unitaria, caracterizada porque comprende una matriz de película delgada soluble en agua, en donde a) dicha matriz de película comprende al menos un polímero de matriz soluble en agua; b) dicha matriz de película comprende 10-200 microgramos de estradiol, o una cantidad equivalente para uso terapéutico de un hidrato de estradiol o una cantidad equivalente para uso terapéutico de un éster de estradiol aceptable para uso farmacéutico; y c) dicha matriz de película tiene un espesor menor que 300 micrometros.
ARP090100515A 2008-02-13 2009-02-13 Sistemas de administracion de drogas que contienen estradiol AR070375A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08002633 2008-02-13

Publications (1)

Publication Number Publication Date
AR070375A1 true AR070375A1 (es) 2010-03-31

Family

ID=39365963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100515A AR070375A1 (es) 2008-02-13 2009-02-13 Sistemas de administracion de drogas que contienen estradiol

Country Status (27)

Country Link
US (1) US20110097405A1 (es)
EP (1) EP2249803A2 (es)
JP (1) JP2011511823A (es)
KR (1) KR20100125309A (es)
CN (1) CN101945646A (es)
AR (1) AR070375A1 (es)
AU (1) AU2009214193A1 (es)
BR (1) BRPI0908477A2 (es)
CA (1) CA2714340A1 (es)
CL (1) CL2009000326A1 (es)
CO (1) CO6290633A2 (es)
CR (1) CR11632A (es)
DO (1) DOP2010000252A (es)
EA (1) EA201001245A1 (es)
EC (1) ECSP10010400A (es)
IL (1) IL206640A0 (es)
MA (1) MA32073B1 (es)
MX (1) MX2010008940A (es)
NZ (1) NZ586666A (es)
PA (1) PA8816001A1 (es)
PE (1) PE20091471A1 (es)
TN (1) TN2010000302A1 (es)
TW (1) TW200940095A (es)
UA (1) UA102680C2 (es)
UY (1) UY31660A1 (es)
WO (1) WO2009101021A2 (es)
ZA (1) ZA201006517B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
US9822257B2 (en) 2012-07-23 2017-11-21 Crayola Llc Dissolvable films and methods of using the same
KR102091852B1 (ko) * 2015-03-02 2020-03-23 코로나리콘셉츠 엘엘씨 Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE4426709A1 (de) * 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CN1240387C (zh) * 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
WO2001077138A1 (de) * 2000-04-12 2001-10-18 Schering Aktiengesellschaft 8β-SUBSTITUIERTE-11β-PENTYL-UND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENDERIVATE
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
WO2002092102A2 (en) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
WO2003009831A1 (en) * 2001-07-27 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
MXPA04008185A (es) * 2002-02-21 2004-11-26 Schering Ag Composiciones farmaceuticas que comprenden uno o mas esteroides, uno o mas componentes de tetrahidrofolato y vitamina b12.
CA2530843A1 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
KR20060126688A (ko) * 2003-12-09 2006-12-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약물-함유 입자 및 그 입자를 함유하는 고형 제제
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
WO2006127879A1 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Flexible solid dosage forms and methods of making and using the same
DE102005058569B4 (de) * 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
EP1867321A3 (en) * 2006-06-07 2008-11-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment

Also Published As

Publication number Publication date
CL2009000326A1 (es) 2010-07-19
US20110097405A1 (en) 2011-04-28
ZA201006517B (en) 2014-02-26
ECSP10010400A (es) 2010-09-30
MA32073B1 (fr) 2011-02-01
WO2009101021A2 (en) 2009-08-20
TW200940095A (en) 2009-10-01
CR11632A (es) 2010-10-05
IL206640A0 (en) 2010-12-30
DOP2010000252A (es) 2010-08-31
AU2009214193A1 (en) 2009-08-20
MX2010008940A (es) 2010-10-05
EP2249803A2 (en) 2010-11-17
BRPI0908477A2 (pt) 2018-03-27
CN101945646A (zh) 2011-01-12
PE20091471A1 (es) 2009-10-25
UA102680C2 (ru) 2013-08-12
CO6290633A2 (es) 2011-06-20
JP2011511823A (ja) 2011-04-14
KR20100125309A (ko) 2010-11-30
TN2010000302A1 (en) 2011-11-11
CA2714340A1 (en) 2009-08-20
EA201001245A1 (ru) 2011-04-29
WO2009101021A3 (en) 2009-12-30
UY31660A1 (es) 2009-09-30
NZ586666A (en) 2012-04-27
PA8816001A1 (es) 2009-09-17

Similar Documents

Publication Publication Date Title
ES2524556T3 (es) Composiciones farmacéuticas
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
CR20110072A (es) Sistema de administración de drogas que contiene progestina
MX343867B (es) Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
EA201001244A1 (ru) Система доставки лекарственного средства со стабилизирующим эффектом
CL2009001556A1 (es) Sistema de administración transdermica de fármacos que comprende una capa que contiene fármaco que comprende una matriz polimérica que contiene estradiol como unico fármaco; método de elaboración; útil para administrar estradiol.
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
BRPI0719009B8 (pt) mecanismo de dosagem e acionamento destinado a dispositivos de liberação de fármacos
CO6160297A2 (es) Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
AR073704A1 (es) Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina
WO2007103293A3 (en) Ethanol-resistant sustained release formulations
WO2008146178A3 (en) A novel tablet dosage form
PA8815501A1 (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa
PE20081301A1 (es) Tabletas de bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
CR20110278A (es) Cartucho, un dispensador de medicamentos para porciones de medicamentos sólidos y el uso del cartucho y del dispensador de medicamentos
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
CL2012001404A1 (es) Composicion farmaceutica que comprende microparticulas compresibles recubiertas de farmaco, un recubrimiento de liberacion modificada, enmascarador del sabor, que comprende un polimero insoluble en agua y un recubrimiento compresible con un edulcorante no polimero sobre ella; composicion de tabletas de rapida desintegracion oral; metodo de preparacion.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
AR070375A1 (es) Sistemas de administracion de drogas que contienen estradiol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal